The pitch sounds almost too simple: turn a smartphone into an eye clinic. Strap on a camera attachment, fire up an app, and suddenly that glaucoma screening or diabetic retinopathy check—services usually confined to well-equipped hospitals—can happen in a village health post or a rural school.
C3 Med-Tech, an Ahmedabad outfit with backing from IIT Madras, has been refining this proposition since 2019. Last June, the company landed its first equity check: INR 2 crore (roughly $240,000) from Industrial Metal Powders, a Southeast Asian manufacturer better known for custom surgical implants than venture bets on healthtech. The investment, facilitated by Pune's INFSPL advisory firm, is earmarked for global expansion, marketing muscle, and hiring ophthalmology experts who can lend clinical credibility to what remains a tech-forward promise.
In India, where the World Health Organization estimates preventable blindness affects millions, the distance between diagnosis and treatment isn't always measured in miles. Sometimes it's infrastructure. Sometimes it's cost. C3's founder, Yash Nagarsheth—a mechanical engineer who studied at Drexel and the University of Michigan before returning home—has bet on portability as the wedge. The devices are light, battery-powered, designed to run for hours without a wall socket. They attach to smartphones most clinicians already carry.
Whether that's enough to crack a crowded, increasingly AI-obsessed market is the question investors and health officials are now sizing up.
Four Devices, One Workflow
C3's product line breaks down into four smartphone-compatible tools, each addressing a slice of ophthalmic care.
The C3 Fundus Cam is a portable fundus camera for imaging the posterior segment—the back of the eye—where diabetic retinopathy, retinopathy of prematurity (ROP), and glaucoma leave their marks. Battery life runs four to six hours, long enough for field work in settings where electricity is unreliable.
Then there's the C3 Vision, a portable slit lamp offering 12.5x magnification for anterior segment exams. Think cataracts, corneal abrasions, infections—conditions that need close-up scrutiny but don't always require a hospital visit.
The company also sells a Slit Lamp Imaging System—essentially a smartphone adapter that clamps onto traditional table-mounted slit lamps via what C3 describes as a patented swivel mechanism. And finally, a Surgery Recording System for capturing live ophthalmic procedures, complete with plug-and-play setup and real-time viewing.
All four integrate with C3's proprietary telemedicine app. The workflow is straightforward: capture images on-site, upload them for remote review, share via the app, email, or even WhatsApp. It's a model built for India's fragmented healthcare landscape, where a single ophthalmologist might serve tens of thousands of patients across districts.
The AI Angle—and the Opacity
Here's where things get murky.
The June funding announcement leaned heavily on "AI-enabled" capabilities for real-time disease detection. That's a compelling hook, especially in a sector where algorithmic screening is rapidly becoming table stakes. But C3's website and product documentation focus almost exclusively on imaging and telemedicine workflows. Details on the AI itself—which conditions it targets, whether it runs on-device or in the cloud, what sensitivity and specificity it achieves—are conspicuously absent.
No published validation studies surface. No regulatory filings clarify whether the AI has undergone clinical trials or received clearance from bodies like the FDA or India's Central Drugs Standard Control Organisation. Nagarsheth has told reporters the devices enable real-time detection, but the technical scaffolding remains vague.
That opacity matters, because competitors have published their data. Remidio's Medios DR AI, for instance, runs offline on handheld devices, delivering diabetic retinopathy results in under 15 seconds, with CE and Singapore's Health Sciences Authority approval to boot. Eyenuk's EyeArt has FDA clearance for autonomous DR screening. AEYE Health launched a portable, FDA-cleared autonomous solution last June—same month C3 announced its funding.
In other words, the bar for transparency isn't hypothetical. It's already been set.
The Deployment Footprint—With Caveats
C3 claims more than 700 installations globally, a figure that climbed to 900 in later LinkedIn updates. The company lists deployments across India, the U.S., South America, Egypt, various African countries, Dubai, Oman, Bangladesh, Singapore, Malaysia, and the Philippines. That's an impressive geographic spread for a five-year-old startup.
The company also states its products are "US FDA-approved." A search of the FDA's 510(k) database under "C3 Med-Tech," however, returns no matching clearances. It's possible the devices are registered under a different entity name, or perhaps they fall into a category that doesn't require 510(k) submission. Either way, the regulatory status would benefit from clarification—especially as C3 pursues U.S. market share.
The broader AI ophthalmology market is undeniably heating up. Grand View Research pegs the global market at $209.23 million in 2024, with projections hitting $1.36 billion by 2030. In India, public-sector efforts like the AIIMS–Wadhwani AI collaboration have rolled out DR screening apps claiming accuracy north of 95%. Forus Health's 3nethra devices leverage Microsoft Azure IoT Edge for offline AI at the point of care.
C3 is entering a scrum, not a vacuum.
Why a Surgical Implant Manufacturer Is Betting on Eye Screening
Industrial Metal Powders' decision to back C3 is, at first glance, a bit of a head-scratcher. The Bangalore-based firm specializes in custom surgical implants—think orthopedic components, not diagnostics. But the managing director framed the investment as more than financial arbitrage. "This investment is not just about financial returns; it's about addressing a critical need in healthcare," the executive said in media statements.
The rationale, such as it is, hinges on the belief that scalable screening in underserved geographies can generate both impact and returns. For a company entrenched in surgical hardware, diagnostic devices represent a logical adjacency—same customer base (hospitals, clinics), different entry point in the care continuum.
For Nagarsheth, the funding validates a mission he's pursued since founding C3: reducing avoidable blindness through affordable, portable tech. The company has previously pulled in grants from BIRAC BIG '17 and support from IIT Madras's Healthcare Technology Innovation Centre. It's showcased devices at ICMR's G20 health conferences and is slated to present at iROP 2025 in Jaipur, a conference focused on neonatal ROP screening.
The Proof Is in the Data—Whenever It Arrives
The devices are in the field. That much is clear. What's less clear is how they're performing relative to competitors, what clinical outcomes they're driving, and whether the AI layer is delivering on its real-time detection promise.
C3's next test isn't just scaling installations. It's transparency. Can the company produce validation studies that hold up under peer review? Will it secure unambiguous regulatory clearances in key markets? Can it articulate its AI's capabilities in language that clinicians—and, perhaps more importantly, regulators—can evaluate?
The smartphone-as-eye-clinic concept has legs. Remidio, Forus, Eyenuk, and others have proven that. But in a market where algorithmic credibility is increasingly non-negotiable, vague promises of "AI-enabled" screening won't cut it. The data on outcomes, as is often the case in healthtech, may still be catching up to the marketing.
For now, C3 has cash, a growing footprint, and a compelling narrative. Whether that's enough to stand out in a densely packed field—one where the best-funded players have already published their clinical bona fides—remains to be seen.
